San Mateo, CA, United States of America

Paulo A Machicao Tello

USPTO Granted Patents = 7 

 

 

Average Co-Inventor Count = 16.1

ph-index = 2

Forward Citations = 7(Granted Patents)


Location History:

  • San Mateo, CA (US) (2020 - 2021)
  • Oakland, CA (US) (2022 - 2023)

Company Filing History:


Years Active: 2020-2025

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Innovations by Paulo A Machicao Tello

Introduction

Paulo A Machicao Tello is a prominent inventor based in San Mateo, CA. He has made significant contributions to the field of cancer treatment through his innovative research and development of PD-1/PD-L1 inhibitors. With a total of seven patents to his name, Tello's work is at the forefront of medical advancements.

Latest Patents

Tello's latest patents include groundbreaking compounds of Formula (I) that are designed for the treatment of cancer. These patents disclose methods of using said compounds either singly or in combination with additional agents. His work on PD-1/PD-L1 inhibitors showcases the potential for these compounds to significantly impact cancer therapies.

Career Highlights

Throughout his career, Tello has been associated with Gilead Sciences, Inc., a leading biopharmaceutical company. His role at Gilead has allowed him to focus on developing innovative solutions for complex medical challenges. Tello's dedication to research and development has positioned him as a key figure in the fight against cancer.

Collaborations

Some of Tello's notable coworkers include Michael Graupe and Jonathan William Medley. Their collaborative efforts contribute to the innovative environment at Gilead Sciences, Inc., fostering advancements in cancer treatment.

Conclusion

Paulo A Machicao Tello's contributions to the field of cancer treatment through his patents and work at Gilead Sciences, Inc. highlight his importance as an inventor. His ongoing research continues to pave the way for new therapeutic options in oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…